Urokinase: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

19 December 2023

18 August 2023

13 August 2023

2 May 2023

19 April 2023

22 March 2023

24 February 2023

23 January 2023

19 January 2023

17 October 2022

10 October 2022

4 August 2022

16 June 2022

22 May 2021

19 February 2021

30 January 2021

31 December 2020

4 December 2020

12 October 2020

28 August 2020

26 August 2020

23 July 2020

10 July 2020

8 July 2020

19 June 2020

21 May 2020

20 May 2020

14 April 2020

16 December 2019

20 October 2019

29 September 2019

10 September 2019

19 August 2019

16 February 2019

10 October 2018

  • curprev 15:4015:40, 10 October 2018TheRealXYZ talk contribs 12,795 bytes +1,730 Clarified marketed name change. Clarified that both urokinase and TPA breakdown fibrin. There is no supporting literature for pathogenic fibrinogenlysis related to use of either urokinase or TPA when used according to approved product directions, thus removed the prior fibrinogenolysis statement. Clarified differences in use of plasminogen activators (urokinase and TPA) as relates to their activity and fibrin binding or lack thereof. undo Tag: Visual edit

5 December 2017

4 June 2017

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)